HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 89.7%

Neg 89.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Neutral.

Comments

No comments yet. Be the first!

HC Wainwright &amp; Co. Downgrades Summit Therapeutics to Neutral